U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H42N2O5S
Molecular Weight 506.698
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of IXABEPILONE

SMILES

[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C3=CSC(C)=N3

InChI

InChIKey=FABUFPQFXZVHFB-PVYNADRNSA-N
InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/ixabepilone.html | http://www.wikidoc.org/index.php/Ixabepilone | http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500062429.pdf

Ixabepilone is an antineoplastic agent, epothilone and mitotic inhibitor that is FDA approved for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Ixabepilone binds directly to beta-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of alpha-beta-II and alpha-beta-III microtubules. The most common adverse reactions (≥20%) are peripheral sensory neuropathy, fatigue/asthenia, myalgia/arthralgia, alopecia, nausea, vomiting, stomatitis/mucositis, diarrhea, and musculoskeletal pain. Inhibitors of CYP3A4 may increase plasma concentrations of ixabepilone.

Originator

Bristol-Myers Squibb
145
Curator's Comment: # Bristol-Myers Squibb Company

Approval Year

2007
205
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 10.6 µM [EC50]
Substrate
661
 7.3 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
IXEMPRA KIT

Approved Use

IXEMPRA is indicated as monotherapy or in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.

Launch Date

1.19249279E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
252 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022065s002lbl.pdf
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IXABEPILONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2143 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022065s002lbl.pdf
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IXABEPILONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
52 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022065s002lbl.pdf
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IXABEPILONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
28%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022065s002lbl.pdf
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IXABEPILONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Disc. AE: Neuropathic pain...
Other AEs: Anorexia, Stomatitis...
AEs leading to
discontinuation/dose reduction:
Neuropathic pain (grade 3, 1 patient)
Other AEs:
Anorexia (grade 3, 1 patient)
Stomatitis (grade 3, 1 patient)
Neutropenia (grade 4, 1 patient)
Fever (grade 3, 1 patient)
Dehydration (grade 3, 1 patient)
Nausea (grade 3, 1 patient)
Vomiting (grade 3, 1 patient)
Dizziness (grade 3, 1 patient)
Sensory neuropathy (grade 3, 1 patient)
Myalgia (grade 3, 1 patient)
Alopecia (grade 2, 2 patients)
Bilirubin increased (grade 2, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
10 mg/m2 1 times / day multiple, intravenous
Dose: 10 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 3
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
DLT: Neutropenia, Fatigue...
Dose limiting toxicities:
Neutropenia (grade 4, 2 patients)
Fatigue (grade 3, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
6 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
unhealthy, 18-80 years
n = 16
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
Other AEs: Fatigue, Anorexia...
Other AEs:
Fatigue (grade 3, 4 patients)
Anorexia (grade 3, 1 patient)
Mucositis (grade 3, 1 patient)
Neutropenia (grade 3, 13 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
8 mg/m2 1 times / day multiple, intravenous
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
unhealthy, 18-80 years
n = 3
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (grade 4, 3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
6.8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6.8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6.8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
unhealthy, 54 years (range: 22–75 years)
n = 3
Health Status: unhealthy
Condition: recurrent high-grade gliomas
Age Group: 54 years (range: 22–75 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
DLT: Low platelets, Arthralgia...
Dose limiting toxicities:
Low platelets (grade 3, 1 patient)
Arthralgia (grade 3, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
7 mg/m2 1 times / day multiple, intravenous
Dose: 7 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 7 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
unhealthy, 54 years (range: 22–75 years)
n = 3
Health Status: unhealthy
Condition: recurrent high-grade gliomas
Age Group: 54 years (range: 22–75 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
DLT: Febrile neutropenia...
Dose limiting toxicities:
Febrile neutropenia (grade 3, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
50 mg 3 times / day multiple, oral
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
unhealthy, 56 years (range: 27–60 years)
n = 6
Health Status: unhealthy
Condition: refractory advanced cancers
Age Group: 56 years (range: 27–60 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
DLT: Neutropenic sepsis...
Dose limiting toxicities:
Neutropenic sepsis (grade 4, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
40 mg 3 times / day multiple, oral
MTD
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
unhealthy, 69 years (range: 39–75 years)
n = 9
Health Status: unhealthy
Condition: refractory advanced cancers
Age Group: 69 years (range: 39–75 years)
Sex: M+F
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
DLT: Febrile neutropenia...
Other AEs: Mucosal inflammation...
Dose limiting toxicities:
Febrile neutropenia (grade 4, 1 patient)
Other AEs:
Mucosal inflammation (grade 3-4, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
100 mg/m2 single, intravenous
Overdose
Dose: 100 mg/m2
Route: intravenous
Route: single
Dose: 100 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Sex: F
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
Other AEs: Myalgia, Fatigue...
Other AEs:
Myalgia (grade 1, 1 patient)
Fatigue (grade 1, 1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
40 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 40 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / 3 weeks
Co-administed with::
capecitabine(1000 mg/m2 twice daily for 2 weeks followed by 1 week rest)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
Other AEs: Neutropenia...
Other AEs:
Neutropenia (grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Bilirubin increased grade 2, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Alopecia grade 2, 2 patients
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Anorexia grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Dehydration grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Dizziness grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Fever grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Myalgia grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Nausea grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Sensory neuropathy grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Stomatitis grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Vomiting grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Neuropathic pain grade 3, 1 patient
Disc. AE
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Neutropenia grade 4, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Fatigue grade 3, 2 patients
DLT
10 mg/m2 1 times / day multiple, intravenous
Dose: 10 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 3
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Neutropenia grade 4, 2 patients
DLT
10 mg/m2 1 times / day multiple, intravenous
Dose: 10 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
unhealthy, 10 years (range: 2 - 18 years)
n = 3
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/19075272
Anorexia grade 3, 1 patient
6 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
unhealthy, 18-80 years
n = 16
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
Mucositis grade 3, 1 patient
6 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
unhealthy, 18-80 years
n = 16
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
Neutropenia grade 3, 13 patients
6 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
unhealthy, 18-80 years
n = 16
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
Fatigue grade 3, 4 patients
6 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
unhealthy, 18-80 years
n = 16
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
Neutropenia grade 4, 3 patients
DLT
8 mg/m2 1 times / day multiple, intravenous
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
unhealthy, 18-80 years
n = 3
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/12721265
Arthralgia grade 3, 1 patient
DLT
6.8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6.8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6.8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
unhealthy, 54 years (range: 22–75 years)
n = 3
Health Status: unhealthy
Condition: recurrent high-grade gliomas
Age Group: 54 years (range: 22–75 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
Low platelets grade 3, 1 patient
DLT
6.8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6.8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6.8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
unhealthy, 54 years (range: 22–75 years)
n = 3
Health Status: unhealthy
Condition: recurrent high-grade gliomas
Age Group: 54 years (range: 22–75 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
Febrile neutropenia grade 3, 2 patients
DLT
7 mg/m2 1 times / day multiple, intravenous
Dose: 7 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 7 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
unhealthy, 54 years (range: 22–75 years)
n = 3
Health Status: unhealthy
Condition: recurrent high-grade gliomas
Age Group: 54 years (range: 22–75 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/20449631
Neutropenic sepsis grade 4, 1 patient
DLT
50 mg 3 times / day multiple, oral
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
unhealthy, 56 years (range: 27–60 years)
n = 6
Health Status: unhealthy
Condition: refractory advanced cancers
Age Group: 56 years (range: 27–60 years)
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
Mucosal inflammation grade 3-4, 2 patients
40 mg 3 times / day multiple, oral
MTD
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
unhealthy, 69 years (range: 39–75 years)
n = 9
Health Status: unhealthy
Condition: refractory advanced cancers
Age Group: 69 years (range: 39–75 years)
Sex: M+F
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
Febrile neutropenia grade 4, 1 patient
DLT
40 mg 3 times / day multiple, oral
MTD
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
unhealthy, 69 years (range: 39–75 years)
n = 9
Health Status: unhealthy
Condition: refractory advanced cancers
Age Group: 69 years (range: 39–75 years)
Sex: M+F
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/22331549
Fatigue grade 1, 1 patient
100 mg/m2 single, intravenous
Overdose
Dose: 100 mg/m2
Route: intravenous
Route: single
Dose: 100 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Sex: F
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
Myalgia grade 1, 1 patient
100 mg/m2 single, intravenous
Overdose
Dose: 100 mg/m2
Route: intravenous
Route: single
Dose: 100 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Sex: F
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
Neutropenia grade 5
40 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 40 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / 3 weeks
Co-administed with::
capecitabine(1000 mg/m2 twice daily for 2 weeks followed by 1 week rest)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inducer
781

substrate
1737
inducer
389

inhibitor
1767

substrate
1037
inhibitor
1852

substrate
1217
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2A6
707

CYP2B6
810

CYP2C19
1478

CYP2C8
911

CYP2E1
882

CYP3A4/5
278

P-gp
1461
BCRP
561

CYP1A2
1054

CYP2B6
664

CYP2C19
991

CYP2C8
693

CYP2E1
667

CYP3A4/5
85

CYP3A5
395

P-gp
1537
CYP1A2
701

CYP2B6
547
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1650
 inconclusive
CYP1A2
1692
 no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
CYP2A6
739
 no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
CYP2B6
1001
 no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
CYP2C19
1553
 no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
CYP2C8
965
 no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
CYP2C9
1819
 no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
CYP2D6
1891
 no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
CYP2E1
970
 no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
CYP1A2
1692
 no
CYP2B6
1001
 no
CYP2C9
1819
 no
CYP3A4
1925
 no
CYP3A4/5
335
 yes [IC50 15 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
1537
 inconclusive
CYP3A4
1737
 major
yes (co-administration study)
Comment: coadministration with ketoconazole increased AUC by 1.8-fold but no difference in Cmax values; CYP3A4 inhibitors should be used with caution in patients taking ixabepilone.
Page: 30, 34
BCRP
561
 no
CYP1A2
1054
 no
CYP2B6
664
 no
CYP2C8
693
 no
CYP2C9
1037
 no
CYP2E1
667
 no
CYP2C19
991
 yes
CYP2D6
1217
 yes
CYP3A4/5
85
 yes
CYP3A5
395
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:63605
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63605
ChemicalBook
CB61011739
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB61011739
MolPort
MolPort-027-720-838
https://www.molport.com/shop/molecule-link/MolPort-027-720-838
ZINC
ZINC000003993846
http://zinc15.docking.org/substances/ZINC000003993846
PubMed

PubMed

TitleDatePubMed
[Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
2008 Feb
Patents

Patents

JP2006519264A
58
JP2011527579A
29
JP2011529067A
35
JP4658037B2
37

Sample Use Guides

In Vivo Use Guide
40 mg/m2 infused over 3 hours every 3 weeks
Route of Administration: Intravenous
In Vitro Use Guide
Hepatocellular carcinoma cell lines were sensitive to ixabepilone, with the IC50 range 2.5–44.1 nmol/l.
Name Type Language
IXABEPILONE
DASH   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
IXABEPILONE [MART.]
Common Name English
IXABEPILONE [MI]
Common Name English
1S,3S,7S,10R,11S,12S,16R)-7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-((1E)-1-METHYL-2-(2-METHYLTHIAZOL-4-YL)ETHENYL)-17-OXA-4-AZABICYCLO(14.1.0)HEPTADECANE-5,9-DIONE
Common Name English
ixabepilone [INN]
Common Name English
AZAEPOTHILONE B
Common Name English
NSC-747973
Code English
BMS-247550
Code English
IXABEPILONE [USP-RS]
Common Name English
(1R,5S,6S,7R,10S,14S,16S)-6,10-DIHYDROXY-1,5,7,9,9-PENTAMETHYL-14-((E)-1-(2-METHYL-1,3-THIAZOL-4-YL)PROP-1-EN-2-YL)-17-OXA-13-AZABICYCLO(14.1.0)HEPTADECANE-8,12-DIONE
Systematic Name English
IXABEPILONE [USAN]
Common Name English
IXABEPILONE [ORANGE BOOK]
Common Name English
IXABEPILONE [HSDB]
Common Name English
IXABEPILONE [VANDF]
Common Name English
BMS-247550-01
Code English
Ixabepilone [WHO-DD]
Common Name English
IXEMPRA KIT
Brand Name English
IXABEPILONE [JAN]
Common Name English
IXEMPRA
Brand Name English
IXABEPILONE [USP MONOGRAPH]
Common Name English
BMS 247550-01
Code English
17-OXA-4-AZABICYCLO(14.1.0)HEPTADECANE-5,9-DIONE, 7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-((1E)-1-METHYL-2-(2-METHYL-4-THIAZOLYL)ETHENYL)-, (1S,3S,7S,10R,11S,12S,16R)-
Common Name English
Classification Tree Code System Code
LIVERTOX NBK547985
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
NCI_THESAURUS C2584
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
NDF-RT N0000175085
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
WHO-VATC QL01DC04
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
NDF-RT N0000175592
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
WHO-ATC L01DC04
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
Code System Code Type Description
NSC
747973
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
RXCUI
337523
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB04845
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
DAILYMED
K27005NP0A
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
EVMPD
SUB33513
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
FDA UNII
K27005NP0A
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
EPA CompTox
DTXSID70870252
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
USAN
OO-38
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
SMS_ID
100000127487
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
PUBCHEM
6445540
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
CAS
219989-84-1
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
IUPHAR
6824
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
ChEMBL
CHEMBL1201752
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
CHEBI
63605
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
DRUG CENTRAL
1517
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
RS_ITEM_NUM
1354400
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
MESH
C430592
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
MERCK INDEX
m6567
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY Merck Index
HSDB
7738
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
NCI_THESAURUS
C37452
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
WIKIPEDIA
IXABEPILONE
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
INN
8390
Created by admin on Sat Dec 16 16:20:20 UTC 2023 , Edited by admin on Sat Dec 16 16:20:20 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of IXABEPILONE
METABOLITE (PARENT)
Structure of BMS-249798
METABOLITE (PARENT)
Structure of 11-HYDROXY IXABEPILONE
METABOLITE (PARENT)
Structure of IXABEPILONE DIOL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966